Table 3 Follow-up characteristics
MCI | AD dementia | Total | |
|---|---|---|---|
Reason for follow-up (n) | |||
Clinical follow-up | 46 | 18 | 64 |
Clinical trial – screening phase | 5 | 24 | 29 |
Clinical trial – control condition | 37 | 18 | 55 |
Number of EEG recordings (median, range) | 2 (2–4) | 2 (2–3) | 2 (2–4) |
Total follow-up time, months (median, range) | 11.0 (2.6 – 34.8) | 5.9 (2.8 – 35.5) | 7.2 (2.6 – 35.5) |